Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 10, 2026, 7:29 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1201–1224 of 3,925 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: HTN Clear all

Conditions: Hypertension, Heart Failure, Vascular Ischemia, Burns, Chemotherapy Effect, Radiation Injuries, Uveitis, Scleritis, Multiple Sclerosis, Autonomic Neuropathy, Stroke, Intracranial Hemorrhages, TIA, Migraine, Headache, Pain
Interventions: laser speckle flowgraphy; Device
Lead sponsor: Randy Kardon; Other
Eligibility: 18 Years to 90 Years
Enrollment: 1 participant
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Iowa City, Iowa

Conditions: Obesity, Vitamin D Deficiency, Hypertension
Interventions: Vitamin D (cholecalciferol); Dietary Supplement
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years to 64 Years
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Hypertension, Diabetes, Cardiovascular Disease
Interventions: Carvedilol, Spironolactone, Usual care; Drug · Other
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 40 Years to 85 Years
Enrollment: 58 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2020
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Adverse Pregnancy Outcome
Interventions: Lovenox 40mg; Drug
Lead sponsor: Endeavor Health; Other
Eligibility: 18 Years to 60 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Evanston, Illinois

Conditions: Pulmonary Hypertension
Interventions: bosentan, placebo; Drug
Lead sponsor: Actelion; Industry
Eligibility: 12 Years and older
Enrollment: 185 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2011
U.S. locations: 6
States / cities: Birmingham, Alabama • Torrance, California • Boston, Massachusetts + 3 more

Conditions: Cardiovascular Diseases, Heart Diseases, Hypertension
Interventions: Nicotine Replacement Therapy, Diet; Drug · Behavioral
Lead sponsor: Mark Vander Weg; Other
Eligibility: Not listed
Enrollment: 139 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2011
U.S. locations: 2
States / cities: Iowa City, Iowa • Rochester, Minnesota

Conditions: Pulmonary Arterial Hypertension
Interventions: mHealth Intervention, Usual Care; Device
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 10 Years to 21 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2030
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: HIV, Hypertension, Hypercholerolemia, Type 2 Diabetes
Interventions: Preventative health review invitation early in SNAP cycle, Financial counseling invitation early in the SNAP cycle, Aim 3 follow-up call early in the SNAP period, Preventative health review invitation late in SNAP cycle, Financial counseling invitation late in the SNAP cycle, Aim 3 follow-up call late in the SNAP cycle; Other
Lead sponsor: University of Pennsylvania; Other
Eligibility: 50 Years and older
Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2029
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Hypertension, Diastolic Dysfunction
Interventions: valsartan, amlodipine; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 45 Years and older
Enrollment: 229 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 1
States / cities: USA, New Jersey

Conditions: Hypertension
Interventions: Telephone behavioral education, Computer behavioral education; Behavioral
Lead sponsor: US Department of Veterans Affairs; Federal
Eligibility: Not listed
Enrollment: 544 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2005
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Intrahepatic Cholangiocarcinoma (Icc), Cholangiocarcinoma, Other Solid Tumors, Adult, FGFR2 Gene Fusion/Rearrangement, FGFR2 Gene Amplification, FGFR2 Gene Short Variants, FGFR3 Gene Fusion/Rearrangement, FGFR3 Gene Amplification, FGFR3 Gene Short Variants, FGFR2 Genetic Alterations, FGFR3 Genetic Alterations, Advanced Solid Tumors
Interventions: CGT4859; Drug
Lead sponsor: Cogent Biosciences, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 110 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 12
States / cities: Palo Alto, California • Jacksonville, Florida • Tampa, Florida + 9 more

Conditions: Hypertension, Retinal Disorder, Cognitive Impairment
Interventions: Not listed
Lead sponsor: Emory University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 234 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2020
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Pre-eclampsia
Interventions: Ultrasound; Device
Lead sponsor: Antonios Likourezos; Other
Eligibility: 18 Years to 55 Years · Female only
Enrollment: 186 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Brooklyn, New York

Conditions: Hypertension
Interventions: baxdrostat; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 55 Years · Male only
Enrollment: 8 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Hypertension, Coronary Artery Disease
Interventions: Verapamil SR/Trandolapril/Hydrochlorothiazide (HCTZ), Atenolol/HCTZ/Trandolapril; Drug
Lead sponsor: University of Florida; Other
Eligibility: 50 Years and older
Enrollment: 22,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1997 – 2003
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: Uncontrolled Hypertension, Cardiovascular Risk Factor
Interventions: Positive Psychological Intervention; Behavioral
Lead sponsor: University of Illinois at Urbana-Champaign; Other
Eligibility: 18 Years and older
Enrollment: 126 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Hypertension, Portal
Interventions: GR-MD-02, Placebo; Drug
Lead sponsor: Galectin Therapeutics Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 162 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 46
States / cities: Los Angeles, California • Sacramento, California • San Diego, California + 39 more

Conditions: Healthy Volunteers
Interventions: 13mg Bimatoprost Ocular Insert; Drug
Lead sponsor: ForSight Vision5, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 11 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015
U.S. locations: 1
States / cities: Artesia, California

Conditions: Hypertension, Renal Transplant
Interventions: Placebo, Allopurinol; Drug
Lead sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); NIH
Eligibility: 6 Years to 18 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Obesity, Hypertension, Hypercholesterolemia, Hyperglycemia
Interventions: Asynchronous, eLearning Intervention; Other
Lead sponsor: University of Illinois Chicago; Other
Eligibility: 18 Years and older
Enrollment: 274 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Hypertension, Vascular Diseases, Cardiovascular Diseases, Chronic Kidney Diseases, Diabetes Mellitus
Interventions: Multi-Organ Denervation Gemini System; Device
Lead sponsor: Medtronic Vascular; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 175 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 12
States / cities: Stanford, California • Orlando, Florida • Safety Harbor, Florida + 9 more

Conditions: Hypertension
Interventions: Device guided breathing RESPeRATE, Isometric hand grip Zona Plus; Device
Lead sponsor: University of Michigan; Other
Eligibility: 21 Years and older
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Hypertension
Interventions: Text messages; Behavioral
Lead sponsor: Columbia University; Other
Eligibility: 18 Years to 85 Years
Enrollment: 140 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: New York, New York

Conditions: Hypertension
Interventions: Cellular Home blood pressure (BP) monitoring; Device
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years to 85 Years
Enrollment: 540 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: San Francisco, California

Search by objective public record fields.

LSFG-SKIN, Laser Speckle Flowgraphy

Vitamin D Supplementation Reduces Renin-Angiotensin System Activity in Obesity

Biomarker Guided Therapies in Stage A/B Heart Failure

Using Placental Pathology to Prevent Recurrent Adverse Pregnancy Outcomes: A Pilot Project

Efficacy and Safety of Oral Bosentan in Pulmonary Arterial Hypertension Class II

Preventing Weight Gain and Controlling Blood Pressure During Smoking Cessation in Hypertensive Smokers

Mobile Health Intervention to Improve Exercise in Pediatric PH

Tracking Income Dynamics and Everyday Health Study

The Effects of Systolic Blood Pressure Lowering on Diastolic Function Using Valsartan + Amlodipine in Patients With Hypertension and Diastolic Dysfunction

Study to Lower Veterans BP: Patient/Physician Intervention

A Study of an FGFR2/3 Inhibitor (CGT4859) in Patients With Cholangiocarcinoma and Other Advanced Solid Tumors

DETECT and Retinal Outcomes in Hypertension

Thoracic Ultrasonography for Pulmonary Edema in Patients With Pre-Eclampsia

Phase 1 Study to Determine the Metabolism and Clearance of Baxdrostat

INVEST: INternational VErapamil SR Trandolapril STudy

Positive Psychology Intervention for Spanish-speaking Hispanic/Latino Adults at Risk for Cardiovascular Disease

Clinical Trial to Evaluation the Safety and Efficacy of GR-MD-02 for the Treatment of Liver Fibrosis and Resultant Portal Hypertension in Patients With Nash Cirrhosis

Bimatoprost Ocular Insert Pharmacokinetic Study

Allopurinol for Renal Transplant Associated Hypertension in Children

HealthMatters@24/7 eLearning for People Supporting Adults With Intellectual and Developmental Disabilities

SPYRAL GEMINI Pilot Study

Assessing Alternative Approaches for Blood Pressure Control: A3BC Trial

Retail Outlet Health Kiosk Hypertension Trial

Remote Monitoring for Equity in Advancing Control of Hypertension